TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies.
TWiV 888: Molnupiravir with Richard Plemper
- April 14, 2022
- Tagged as: antiviral drug, coronavirus, COVID-19, favipiravir, molnupiravir, pandemic, remdesivir, ribavirin, SARS-CoV-2, viral, virus, viruses
Richard joins TWiV to discuss the SARS-CoV-2 antiviral drug Molnupiravir , including how it was discovered, its mechanism of action, whether it is a mutagen for cells, and the future of drugs for treatment of COVID-19.
TWiV describes the identification of a monoclonal antibody that provides broad protection against a variety of hantaviruses, and development of an oral remdesivir-like antiviral that ameliorates viral disease in mice.
TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitro would not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in variants of concern, in the absence of immune selection.
TWiV 819: How to stall a copy machine
- October 21, 2021
- Tagged as: coronavirus, COVID-19, pandemic, RdRp, remdesivir, RNA dependent RNA polymerase, SARS-CoV-2, viral, virology, virus, viruses
TWiV explains how remdesivir inhibits the SARS-CoV-2 RNA polymerase: the drug is incorporated into the growing RNA chain and causes synthesis to stall when the drug clashes with an amino acid in the active site.
TWiV 686: COVID-19 clinical update #38 with Dr. Daniel Griffin
- November 28, 2020
- Tagged as: clinical report, COVID-19, Daniel Griffin, monoclonal antibody, pandemic, remdesivir, SARS-CoV-2, viral, virology, virus, viruses
Daniel Griffin provides his weekly clinical report on COVID-19, including new post-exposure guidelines from CDC, clinical trials of Remdesivir and convalescent plasma, FDA EUA for baricitinib and Regeneron’s monoclonal antibody and more.
TWiV Special: Presidential COVID-19 with Dr. Daniel Griffin
- October 5, 2020
- Tagged as: coronavirus, COVID-19, Donald Trump, monoclonal antibody, pandemic, Regeneron, REGN-COV2, remdesivir, SARS-CoV-2, US President, viral, virology, virus, viruses
Daniel Griffin discusses President Trump’s case of COVID-19, including the clinical course, the medications he received and why, and expectations for the next few weeks.
TWiV 622: Nonhuman primate model for COVID-19 with Emmie de Wit
- June 2, 2020
- Tagged as: ChAdOX vaccine candidate, COVID-19, nonhuman primate, remdesivir, rhesus macaque, SARS-CoV-2, viral, virology, virus, viruses
Emmie de Wit joins TWiV to explain her work on the pathogenesis of infection with SARS-CoV-2 in rhesus macaques, including studies on remdesivir and vaccine candidate.
TWiV 613: Jenner, vaccines, and COVID-19
- May 14, 2020
- Tagged as: ChAdOx, COVID-19, Jenner Institute, pandemic, remdesivir, SARS-CoV-2, Vaccine, viral, virology, virus, viruses
Vincent, Kathy and Rich explain the Jenner Institute’s SARS-CoV-2 vaccine, the NIH decision to stop the Remdesivir study, and answer listener questions.
TWiV 608: Daniel Griffin’s COVID-19 clinical report
- May 1, 2020
- Tagged as: blood clot, clinical report, coronavirus, COVID-19, embolism, pandemic, remdesivir, SARS-CoV-2, viral, virology, virus, viruses
Daniel Griffin updates the clinical situation with COVID-19 patients, followed by analysis of the remedesivir clinical trial results, and answers listener questions.